°®¶¹´«Ã½ has developed a white paper providing an overview of current laboratory challenges surrounding MPXV testing. The paper focuses on biosafety and risk assessment considerations related to specimen handling as well as recommendations for clinical specimen inactivation prior to MPXV testing. It also includes introduction of mpox viral infections, specimen types for diagnostic testing, and a link to ASM’s MPXV inactivation guidance for nucleic acid testing validation.
This guideline was developed on behalf of the American Society for °®¶¹´«Ã½ Clinical and Public Health °®¶¹´«Ã½ Committee, Laboratory Practices Subcommittee.
Contact Information
ASM's Clinical and Public Health °®¶¹´«Ã½ Committee, clinmicro@asmusa.org.